Yeah, so it was a very exciting debate. And I suppose I start the argument by saying that choosing whether it’s safe to re-irradiate is a really difficult question and one that we currently don’t always have an answer for. So what we do use is an idea of what dose a patient has received the first time, how long it’s been since the first year of radiation, what other treatment has been received, those kind of treatment-related questions...
Yeah, so it was a very exciting debate. And I suppose I start the argument by saying that choosing whether it’s safe to re-irradiate is a really difficult question and one that we currently don’t always have an answer for. So what we do use is an idea of what dose a patient has received the first time, how long it’s been since the first year of radiation, what other treatment has been received, those kind of treatment-related questions. But the reality is that even though we may have two patients treated the exact same way with the exact same dose, the outcomes could be very different. So my argument in the debate is that what’s underlying is really biology and until we understand the biology and take it into account, it’s going to be very difficult to serve the patients the best way.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
